The Center for Biomedical Research (CBR) research program focuses on five areas:
- Therapeutic Drug Evaluation
- Oncology Clinical Study Management (Medical & Radiation Oncology)
- Pharmacogenics
- Radiotracer Development
- Physician Clinical Research Training
Therapeutic Drug Evaluation: CBR is significantly active in the evaluation of therapeutic drugs. CBR currently provides oversight and principal investigators for over 20 open clinical trials and over 90 in follow up spanning major disease sites such as Breast, Lung, Colon, and many other cancer diagnoses. These trials cover curative, first and second line therapeutics.
Oncology Clinical Study Management: CBR specializes in managing oncology clinical trials from start to finish in both medical and radiation oncology. As members of ECOG, CTSU, RTOG/NRG Oncology we manage the complete spectrum of clinical trials from cooperative groups to pharmaceutical sponsors to investigator directed clinical trials. These clinical trials vary in range from observational/registry trials to Phase II – Phase IV trials.
Pharmacogenomics: Medical diagnostics and therapeutics will experience a significant shift over the next 2-10 years as the old “one treatment fits all” model is replaced with a more personalized treatment and disease tracking system based on genomic make-up. Patients will be grouped into subsets based on the presence or absence of specific gene mutations for each disease. Today, a growing area of interest and research is therefore de-coding the relevance of DNA profiles. CBR currently participates in a biobank blood draw trial that is soon to be significantly expanded to cover a wide breadth of diagnoses.
Radiotracer Development: With access to an on-site cyclotron and radiochemistry system, CBR plans a program to assist in the development of new radiolabeled tracers and biomarkers for use in companion diagnostics, assessing pharmacological effects, molecular drug delivery efficiencies and drug retention/uptake studies. CBR has participated in one Phase II trial for a new PET myocardial perfusion imaging agent and was recently opened the Phase III of this same agent.
Physician Clinical Research Training: As clinical research regulations continues to grow more complex it is critically important that principal investigators are up to date on all regulations and good clinical practices. CBR provides educational programs to assure that principal investigators are informed and educated on all aspects of new clinical research regulations and good clinical practices. Whether one time sessions or monthly meetings CBR meets the needs of our many physician clients.
